Effects of VR and MR Exergaming on Mood and Executive Function During Workplace Microbreaks
NCT06889597, Not applicable, Completed, Akdeniz University
Trial 10
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
| Field | Value | Source |
|---|---|---|
| Title | Effects of VR and MR Exergaming on Mood and Executive Function During Workplace Microbreaks | ClinicalTrials.gov |
| NCT number | NCT06889597 | ClinicalTrials.gov |
| Status | Completed | ClinicalTrials.gov |
| Phases | Not applicable | ClinicalTrials.gov |
| Enrollment | 28 participants, actual | ClinicalTrials.gov |
| Lead sponsor | Akdeniz University | ClinicalTrials.gov |
| Conditions | Exergame, Active Video Games (AVG), Mood State, Executive Function (Cognition) | ClinicalTrials.gov |
| Interventions | Experimental, Experimental | ClinicalTrials.gov |
| First posted | 2025-03-21 | ClinicalTrials.gov |
| Last updated | 2025-09-17 | ClinicalTrials.gov |
Registered outcomes 5
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description | Source |
|---|---|---|---|---|
| Primary | Executive Functions | Baseline and immediately post-intervention (within 5 minutes after the session | Executive functions will be assessed using the PEBL Victoria Stroop Test. This test evaluates cognitive control, reaction time, and error rates in different experimental conditions. To eliminate learning effects, each participant will complete two practice trials before the experimental session. The test consists of three phases (1. Neutral words (words without color conflict), 2. Congruent words (words where the meaning matches the text color), 3.Incongruent words (words where the meaning differs from the text color). Participants will be instructed to identify the color of the word as quickly and accurately as possible. Reaction times (in milliseconds) and error rates will be recorded. | ClinicalTrials.gov |
| Primary | Mood State | Baseline and immediately post-intervention (within 5 minutes after the session) | Participants' mood states will be assessed using the Positive Affect subscale of the Positive and Negative Affect Schedule (PANAS). PANAS is a widely used self-report instrument designed to measure two distinct dimensions of affective states: Positive Affect (PA) and Negative Affect (NA). However, in this study, only the PA subscale will be utilized. This decision is based on the study's focus on the short-term affective benefits of VR and MR exercise, as physical activity is predominantly linked to improvements in positive emotions rather than significant reductions in negative affect. Additionally, since negative emotions may not exhibit substantial changes in a single-session exercise context, analyzing only positive affect provides a clearer understanding of the intervention's psychological benefits. | ClinicalTrials.gov |
| Secondary | Heart Rate | Baseline and during intervention | Heart rate will be measured using a Polar H10 chest strap sensor at two time points: pre-exercise and during the session. All HR data will be recorded in real time via the Polar Flow application. The HR measurements will be used to assess the physiological load of the exercise and compare differences across conditions. | ClinicalTrials.gov |
| Secondary | Perceived Exertion | Baseline and immediately post-intervention (within 5 minutes after the session) | Subjective physical exertion will be evaluated using the Borg Rating of Perceived Exertion (RPE) Scale (6-20) before and after each session. This scale measures subjective physical effort perception and is widely used for assessing exercise intensity. | ClinicalTrials.gov |
| Secondary | Intention to Continue | Immediately post-intervention (within 5 minutes after the session) | Participants' intention to engage in VR and MR-based exercise in the future will be measured using a 7-point Likert scale (1 = Not at all likely, 7 = Definitely will repeat). Higher scores indicate a stronger intention to continue using VR/MR-based exercise programs in the future. This outcome will help determine the long-term engagement potential of immersive exercise formats. | ClinicalTrials.gov |
Outcomes 0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
| Type | Outcome | Time frame | Population | Units | Measured as | Source |
|---|
Results by group 0
Each measurement the trial posted, group by group, in the words and numbers it posted.
| Outcome | Group | Category | Value | Spread | Units | Source |
|---|
Participant flow 0
How many started, completed or left each group, period by period.
| Period | Milestone | Group | Participants | Units counted | Source |
|---|
Adverse events 0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
| Type | Event | Organ system | Group | Affected | At risk | Events | Source |
|---|
Adverse event totals 0
The totals the trial posted for each group.
| Total | Group | Affected | At risk | Source |
|---|
Papers 1
The papers the trial lists on ClinicalTrials.gov.
| PMID | Listed as | Source |
|---|---|---|
| 42482558 | DERIVED | PubMed |
Grants 0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
| Project | Title | Principal investigators | Organization | Funder | Fiscal years | Source |
|---|
Trial comparisons 0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
| Comparison | Source |
|---|
Tests 1
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
| Test | Named as | Source |
|---|---|---|
| Stroop Color-Word Test | Primary outcome | ConductCognition |
Source 5
| Field | Value | Source |
|---|---|---|
| Release | trials-2026-11-12-0.4.0 | ClinicalTrials.gov |
| Release manifest SHA-256 | 0f4a8d8c48aee2a7573ae0fa94ecbeab70c1adbe449bbc95c424bc7d3e97b9d4 | ClinicalTrials.gov |
| Registry capture | 2026-11-12 | ClinicalTrials.gov |
| Results copy, AACT | 2026-03-23 | ClinicalTrials.gov |
| NIH clinical studies file | 2026-11-13 | ClinicalTrials.gov |
Release trials-2026-11-12-0.4.0
ClinicalTrials.gov's posted results, through CTTI's AACT: ClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299 ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
ClinicalTrials.gov: none stated ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
NIH RePORTER's clinical studies and project files: Public domain (NIH RePORTER)